Reports on a study of men with co-occurring substance abuse and antisocial personality disorders and the potential benefit of judicially mandated addiction treatment.
Describes NIDA’s drug abuse and addiction research priorities for the use of the American Recovery and Reinvestment Act of 2009 funds.
Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.
Reports on an animal study showing that methadone, normally used as a therapy for opioid abuse, may prove to be an effective treatment for cocaine abuse.
Remembers Henry I. "Hank" Yamamura, an eminent neuropharmacologist who pioneered radioligand binding assays, contributing valuable knowledge about neurotransmitter transporters and receptors.
Reports on a link between mental disorders, including mood, anxiety, or personality disorder and nicotine dependence in pregnancy women.
Reports on study results indicating a medication prescribed for schizophrenia and manic phases of bipolar disorder shows promise as a cocaine addiction treatment.
Offers an overview of some of the NIDA-supported innovative research achievements to reduce the health and social effects of drug abuse and addiction.